Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Working Capital Changes (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Working Capital Changes for 15 consecutive years, with $4818.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 99.38% to $4818.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4818.0 through Dec 2025, down 99.75% year-over-year, with the annual reading at $5078.0 for FY2025, 63.12% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $4818.0 at Aytu Biopharma, up from -$484000.0 in the prior quarter.
  • The five-year high for Other Working Capital Changes was $1.8 million in Q2 2023, with the low at -$2.9 million in Q2 2025.
  • Average Other Working Capital Changes over 5 years is -$81889.2, with a median of $615.0 recorded in 2023.
  • The sharpest move saw Other Working Capital Changes soared 475000.0% in 2021, then crashed 297158.82% in 2024.
  • Over 5 years, Other Working Capital Changes stood at $9502.0 in 2021, then plummeted by 98.95% to $100.0 in 2022, then surged by 515.0% to $615.0 in 2023, then skyrocketed by 126729.27% to $780000.0 in 2024, then plummeted by 99.38% to $4818.0 in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $4818.0, -$484000.0, and -$2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.